Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...
TMCnet11m
Contentful Reveals Next Phase of Growth with Modern Digital Experience Vision, Product Innovation, and New Strategic Partnerships
"Brands are frustrated by monolithic, bloated DXP solutions that aren't fit for purpose," said Contentful CEO Karthik Rau. "In this constantly evolving technology landscape, a flexible new approach is ...